Research analysts covering EUPRAXIA PHARMACEUTICALS.
Recent press releases and 8-K filings for EPRX.
Eupraxia Pharmaceuticals Reports Positive RESOLVE Trial Data for EP-104GI
EPRX
New Projects/Investments
Guidance Update
- Eupraxia Pharmaceuticals announced positive 12-week and 36-week tissue health data from its ongoing Phase 1b/2a RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (EoE).
- At week 12, the highest dosed patients achieved near-complete normalization of tissue health, with lower doses maintaining improvements in tissue health out to week 36.
- Clinical remission was achieved by 58% of patients at 12 weeks, maintained by 79% at 24 weeks, and 67% at 52 weeks in patients with at least 60% of their esophagus treated.
- EP-104GI has been well tolerated, with over 200 patient-months of follow-up reporting no Serious Adverse Events or cases of oral candidiasis.
- Top-line data from the Phase 2b part of the RESOLVE trial is anticipated in Q3 2026.
Jan 8, 2026, 5:02 PM
Eupraxia Pharmaceuticals Reports Q3 2025 Financial Results and Business Update
EPRX
Earnings
New Projects/Investments
Guidance Update
- Eupraxia Pharmaceuticals reported a net loss of $6.4 million for the three months ended September 30, 2025, and a net loss of $21.9 million for the nine months ended September 30, 2025.
- The company completed an $80.5 million public offering on September 24, 2025, issuing 14,636,363 Common Shares at $5.50 per share.
- As of September 30, 2025, Eupraxia Pharmaceuticals had $89.0 million in cash and anticipates this, along with future warrant exercises, will fund operations into the first half of 2028.
- Positive 52-week data from the Phase 1b/2a RESOLVE Trial for EP-104GI were reported, showing durable symptom and tissue responses, with topline data for the Phase 2b portion expected by Q3 2026.
Nov 4, 2025, 9:01 PM
Eupraxia Pharmaceuticals Inc. Closes Public Offering for US$80.5 Million
EPRX
New Projects/Investments
- Eupraxia Pharmaceuticals Inc. closed a public offering on September 24, 2025, issuing 14,636,363 common shares.
- The common shares were offered at a price of US$5.50 per share, resulting in gross proceeds of approximately US$80.5 million.
- The company intends to use the net proceeds primarily for the continued advancement of its product pipeline, including preclinical studies, clinical trials, regulatory submissions, and manufacturing scale-up, as well as for research and development, business development initiatives, and general corporate purposes.
Sep 29, 2025, 8:32 PM
Eupraxia Pharmaceuticals Prices US$70 Million Public Offering
EPRX
New Projects/Investments
- Eupraxia Pharmaceuticals Inc. announced the pricing of a public offering of 12,727,273 common shares at US$5.50 per share, aiming for gross proceeds of approximately US$70 million.
- The company has granted the underwriters a 30-day option to purchase up to an additional 1,909,090 common shares.
- The offering is expected to close on September 24, 2025, subject to customary closing conditions.
- The net proceeds from the offering will primarily be used for the continued advancement of its product pipeline, including preclinical studies, clinical trials, regulatory submissions, and manufacturing scale-up, as well as for research and development of additional pipeline candidates and general corporate purposes.
Sep 23, 2025, 3:07 PM
Eupraxia Pharmaceuticals Announces Positive 1-Year Clinical Results for EP-104GI in EoE Trial
EPRX
New Projects/Investments
- Eupraxia Pharmaceuticals Inc. (EPRX) announced positive 1-year clinical data from its Phase 1b/2a RESOLVE trial for EP-104GI in treating eosinophilic esophagitis (EoE).
- At 12 months, two-thirds of Cohort 5 patients (48mg dose, 4mg per site) remained in clinical remission, and all cohorts followed to 9 months maintained clinically meaningful improvements in tissue health.
- The trial reported no Serious Adverse Events (SAE) or any events of oral or gastrointestinal candidiasis to date.
- The company expects to report additional 12-month data from a larger patient set later this year and anticipates top-line data from the Phase 2b part of the RESOLVE trial in Q3 2026.
Sep 2, 2025, 12:15 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more